Caxton Associates LP Allogene Therapeutics, Inc. Transaction History
Caxton Associates LP
- $2.65 Billion
- Q3 2024
A detailed history of Caxton Associates LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Caxton Associates LP holds 242,102 shares of ALLO stock, worth $472,098. This represents 0.03% of its overall portfolio holdings.
Number of Shares
242,102
Previous 466,110
48.06%
Holding current value
$472,098
Previous $1.09 Million
37.66%
% of portfolio
0.03%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding ALLO
# of Institutions
163Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$36.5 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$32.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$16.2 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$13.7 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$13.4 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $280M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...